Ultragenyx to sell FDA rare pediatric disease PRV for $203M in cash

Ultragenyx Pharmaceutical Inc.

Asset purchase agreement signed October 8, 2026; unnamed buyer pays $203 million in cash at closing.
PRV was awarded by the FDA on September 17, 2026 with approval of FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111.
FAYUVI/UX111 treats pediatric patients with mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo syndrome Type A).
Closing subject to expiration or termination of the HSR antitrust waiting period; agreement to be filed with the FY2026 Form 10-K.
Pact includes customary representations, warranties, covenants and indemnification provisions subject to limitations.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.